May 14, 2020
Armata Pharmaceuticals Announces First Quarter 2020 Results and Provides General Corporate Update
Apr 27, 2020
Thermo Fisher Scientific adds Cefiderocol and Imipenem/Relebactam to manual and automated Antimicrobial Susceptibility Testing Platforms including ARIS HiQ
Mar 19, 2020
Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Results and Provides General Corporate Update
Nov 12, 2019
Armata Pharmaceuticals Announces Third Quarter Results and Provides Corporate and Clinical Update
Oct 31, 2019
Armata Pharmaceuticals Issues Letter to Shareholders
Sep 12, 2019
Armata Pharmaceuticals Announces Development of New Synthetic Phage Candidate Targeting Pseudomonas aeruginosa
Aug 01, 2019
Armata Pharmaceuticals to Provide Corporate Update at the 39th Annual Canaccord Genuity Growth Conference
Jun 18, 2019
Armata Pharmaceuticals to Host Key Opinion Leader Meeting on Bacteriophage-Based Therapeutics on June 26 in New York
May 28, 2019
Armata Pharmaceuticals Announces Publication of Successful Adjunctive Phage Treatment in Cystic Fibrosis Patient
May 09, 2019
C3J Therapeutics and AmpliPhi Biosciences Announce Successful Completion of Merger and Formation of Bacteriophage Company Armata Pharmaceuticals, Inc.
Feb 13, 2019
Public Health Notice - Information for Canadians who have received or are considering medical procedures in Mexico
Nov 13, 2018
2018 Europe Automated Microbiology Market
Oct 04, 2018
Gram-negative bacteria increase mortality, vasopressor use and ICU admission in ILD patients
Sep 10, 2018
IDEXX Pseudalert Test Accepted as Global ISO Standard
May 30, 2018
Geom Therapeutics To Present Data From Antibiotic Drug Development Programs At ASM Microbe
Jan 03, 2018
Locus Biosciences and IDbyDNA Partner to Develop Companion Diagnostic Test for Pseudomonas aeruginosa Infection
Oct 31, 2017
Inhibrx Wins CARB-X Award Of Up To $6.0M To Accelerate Development Of Its Novel Antibody, INBRX-111, To Treat Pseudomonas Infections
Oct 04, 2017
New Nitric Oxide Treatment Eradicates Emerging 'Superbugs'
Sep 14, 2017
Microbiotix and the AMR Centre Announce Co-Development Agreement Targeting Drug Resistant P. aeruginosa in Critically Ill Pneumonia Patients